Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LGMN | Q99538 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72241 | 1.00 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2ATSHRLGMN | |
| SCHEMBL70942 | 0.91 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2ATSHRLGMN | |
| SCHEMBL70943 | 0.91 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2ATSHRLGMN | |
| SCHEMBL72412 | 0.89 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2ATSHRLGMN | |
| SCHEMBL72086 | 0.87 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2ATSHRLGMN | |
| SCHEMBL4942020 | 0.87 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2ATSHRLGMN | |
| SCHEMBL73423 | 0.87 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ATSHRLGMN | |
| SCHEMBL73422 | 0.87 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ATSHRLGMN | |
| SCHEMBL88242 | 0.86 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ATSHRPOLB | |
| SCHEMBL88243 | 0.86 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ATSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | ALDH1A1 216/4885MEN1 4254/4885KMT2A 568/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | ALDH1A1 207/4885MEN1 4337/4885KMT2A 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.